| 标题 |
Efficacy, safety and exploratory analysis of neoadjuvant tislelizumab (a PD-1 inhibitor) plus nab-paclitaxel followed by epirubicin/cyclophosphamide for triple-negative breast cancer: a phase 2 TREND trial |
| 网址 | |
| DOI | |
| 其它 |
期刊:Signal Transduction and Targeted Therapy 作者:Qiang Zhang; Mozhi Wang; Yumeng Li; Hengjun Zhang; Yusong Wang; et al 出版日期:2025-05-25 |
| 求助人 | |
| 下载 | 该求助完结已超 24 小时,文件已从服务器自动删除,无法下载。 |
PDF的下载单位、IP信息已删除
(2025-6-4)